Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

NeuBase Therapeutics Inc (NBSE)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow NeuBase Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.438 +0.016    +3.89%
01/05 - Closed. Currency in USD ( Disclaimer )
  • Volume: 1,183
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.416 - 0.438
Type:  Equity
Market:  United States
NeuBase Therapeutics 0.438 +0.016 +3.89%

NeuBase Therapeutics Company Profile

 
Read the OHR company profile to learn more about the business and the management team. View NeuBase Therapeutics Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

33

Equity Type

ORD

NeuBase Therapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases. The PATrOL-enabled anti-gene therapies are designed to improve upon current genetic medicine strategies by combining the advantages of synthetic approaches with the precision of antisense technologies. Its programs are NT-0100 in HD, NT-0200 in Myotonic Dystrophy Type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD messenger ribonucleic acid (mRNA). The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease mRNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene.

Contact Information

Address 350 Technology Drive Suite 421
Pittsburgh, 15219
United States
Phone 412 763 3350
Fax -

Top Executives

Name Age Since Title
Robert Zamboni - - Chief of Preclinical Development & Member of Scientific Advisory Board
Dov A. Goldstein 55 2019 Independent Chairperson
Eric I. Richman 62 2019 Independent Director
Robert Friedlander - - Chair of Scientific Advisory Board
George McDonald Church 69 2023 Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Board
Peter Nielsen - 2020 Member of Gene Editing & Scientific Advisory Board
Randy Davis - 2020 Member of Scientific Advisory Board
Eriks Rozners - 2020 Member of Gene Editing & Scientific Advisory Board
Gerald J. Mcdougall 56 2021 Independent Director
Danith H. Ly - 2019 Member of Advisory Board
Steven F. Dowdy - 2019 Member of Gene Editing & Scientific Advisory Board
James M. Coull - 2023 Member of Gene Editing Advisory Board
Jeremy Stark - 2023 Member of Gene Editing Advisory Board
Dietrich A. Stephan 54 2019 Founder, President & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NBSE Price Commentary

Write your thoughts about NeuBase Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email